Beyond Limitations: Flexible Manufacturing for Patient Centered Medicine
Webinars | August 27, 2026
As pharmaceutical companies pursue more patient-centric therapies, new approaches are needed to address flexible dosing, adherence, swallowability, and personalized treatment strategies.
Watch an educational webinar featuring experts from Butler University, the Personalized Medicine Coalition, and Aprecia Pharmaceuticals as they discuss emerging approaches to patient-centered drug development and advanced pharmaceutical manufacturing. Explore how patient-centric drug development is driving innovation in dosage form design, flexible dosing, and advanced manufacturing. Learn how FDA and EMA regulations are evolving, how 3D printing is creating competitive advantage now, and what industry experts predict for the future.
You Asked, We Answered
The webinar generated several insightful questions from attendees. Although we were unable to address all of them during the live session, our experts provided follow-up responses. Explore the questions and answers below for additional insights into pharmaceutical 3D printing, flexible dosing, personalized medicine, and emerging manufacturing technologies.
What are advantages 3D printing technology offers in terms of drug loading capacity compared to traditional tablets or capsules?
One of the most differentiated features of Aprecia’s ZipDose™ technology is its ability to accommodate very high API loads while maintaining dosage form performance. Because binder jetting relies on binding powder particles together through the precise application of print fluid, attributes such as compactibility of the API that might affect tablet compression at high drug loads are not a constraint with Aprecia’s 3DP technology. Doses exceeding 1,000 mg of active ingredient have been incorporated into rapidly disintegrating dosage forms, a range that is prohibitive with conventional orally disintegrating tablet (ODT) technologies.
What would be the best practice if a patient dose requirement does not fall in the commercially available doses, specifically for narrow therapeutic index drugs. e.g., warfarin sodium?
This is probably one of the strongest theoretical use cases for pharmaceutical 3D printing. For narrow therapeutic index drugs such as warfarin sodium, individualized dosing is commonly achieved today through combining multiple tablet strengths or tablet splitting. These strategies have limitations and may risk safety and effectiveness.
A validated 3D-printing workflow can manufacture patient-specific dose strengths such as 1.7 mg, 2.3 mg, 4.8 mg for example, rather than just the traditional strengths. While this is a potential application of Aprecia’s 3DP technologies for personalized medicine, the challenge today is regulatory, not technical. Dose accuracy and traceability requirements at patient-specific dosage strengths within a validated design space can be precisely achieved; however, the dispensing of those products to a patient under supervised medical guidance requires regulatory acceptance.
Today, traditional approved dosing regimens remain the standard of care. The value proposition of Aprecia’s 3DP becomes most compelling if decentralized or pharmacy-level manufacturing eventually gains regulatory acceptance.
How applicable is 3D printing to Tetrahydrocanabinol (THC) dosage and drug delivery, particularly with the goal of fast onset, higher bioavailability, and zero bitterness, given that THC is lipohilic and arguably bitter?
While we do not have direct experience working with THC, addressing these challenges is feasible using 3D printing. A detailed target product profile would be needed to understand the intended route of administration and target PK profile to determine the formulation and process strategies required.
The bracketing flexibility of APIs is great, but how do you adapt the scale of the process to the need for individualized dosimetry?
This is probably one of the strongest theoretical use cases for pharmaceutical 3D printing.
Individualized dosing is commonly achieved today through combining multiple tablet strengths or tablet splitting. These strategies have limitations and may risk safety and effectiveness.
Aprecia’s technology is ideally suited to adapt to scale because we have the ability to produce small batch sizes and transition easily to produce alternate product strengths by modifying the number of powder layers, the size and shape of the tablet by altering the digital print image, and/or changing the amount of print fluid applied.
What are the economic advantages of your process versus a traditional pharma approach, for example a classic dispersible tablet with similar attributes?
For a mature, high-volume product, traditional tableting may be economically favorable on direct manufacturing cost. The advantages of 3DP are reduced development time, lower scale-up barriers, greater lifecycle flexibility and IP protection, and reduced overhead.
The 3DP production platforms enable rapid prototyping without tooling changes which translates to speed from early development through clinical supply. Aprecia’s 3D printed dosage forms offer ease of administration and patient acceptability suited for impactful market reach across broad patient populations. Additionally, the unique attributes of 3D printed dosage forms are difficult if not impossible to replicate by a generic competitor.
Any comments on friability of Aprecia’s tablets?Any limitations of the BCS Class of the API?
3D printed tablets are inherently more friable than a compressed tablet. While porosity is an inherent design feature, it enables rapid disintegration. The key engineering challenge is to achieve the desired level of mechanical strength without compromising product performance. This balance is one of many product attributes that our development teams design and optimize throughout formulation and manufacturing process development.
Any limitations of the BCS Class of the API?
Aprecia’s technology has broad API compatibility and BCS class is not an inherent limitation. Strategies to achieve the desired solubility and bioavailability can be effectively combined with 3D printing.
For additional questions or discussion, please contact contact@aprecia.com.